Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Babelova, Andrea ^a   Jansen, Felix ^a,e   Sander, Kerstin ^a,f   Löhn, Matthias ^b   Schäfer, Liliana ^a   Fork, Christian ^a   Ruetten, Hartmut ^b   Plettenburg, Oliver ^b   Stark, Holger ^a   Daniel, Christoph ^c   Amann, Kerstin ^c   Pavenstädt, Hermann ^d   Jung, Oliver ^a   Brandes, Ralf P ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Sanofi Deutschland GmbH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CREATININE; EHT 1864; FIBRONECTIN; GUANOSINE TRIPHOSPHATASE; HYDROLASE INHIBITOR; NEPHRIN; RAC1 PROTEIN; RAMIPRIL; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; SAR 407899; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UREA; WT1 PROTEIN; ISOQUINOLINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRONE DERIVATIVE; QUINOLINE DERIVATIVE; SAR407889A;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PODOCYTE; RENAL PROTECTION; UREA BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ALBUMINURIA; ANIMALS; ISOQUINOLINES; MALE; MICE; PIPERIDINES; PODOCYTES; PYRONES; QUINOLINES; RAC1 GTP-BINDING PROTEIN; RAMIPRIL; RENAL INSUFFICIENCY, CHRONIC; RHOA GTP-BINDING PROTEIN;

EID: 84892375133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080328     Document Type: Article

References (54)

1. Levey AS, Coresh J (2012) Chronic kidney disease. Lancet: 379: 165-180. doi:10.1016/S0140-6736(11)60178-5. PubMed: 21840587.
2. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH (2012) Treatment of chronic kidney disease. Kidney Int: 81: 351-362. doi:10.1038/ki.2011.380. PubMed: 22166846.
3. Brenner BM (1985) Nephron adaptation to renal injury or ablation. Am J Physiol: 249: F324-F337. PubMed: 3898871.
4. Riser BL, Cortes P, Yee J (2000) Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens: 9: 43-47. doi: 10.1097/00041552-200001000-00008. PubMed: 10654824.
5. Kriz W, Elger M, Nagata M, Kretzler M, Uiker S et al. (1994) The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl: 45: S64-S72. PubMed: 8158902.
6. Kretzler M, Koeppen-Hagemann I, Kriz W (1994) Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch: 425: 181-193. PubMed: 7952502.
7. Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest: 108: 1583-1587. doi:10.1172/JCI200114629. PubMed: 11733553.
8. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten DP et al. (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest: 108: 807-816. doi:10.1172/JCI200112367. PubMed: 11560950.
9. Dessapt C, Baradez MO, Hayward A, Dei CA, Thomas SM et al. (2009) Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant: 24: 2645-2655. doi:10.1093/ndt/gfp204. PubMed: 19420102.
10. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J et al. (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int: 65: 30-39. doi:10.1111/j.1523-1755.2004.00362.x. PubMed: 14675034.
11. Miner JH (1999) Renal basement membrane components. Kidney Int: 56: 2016-2024. doi:10.1046/j.1523-1755.1999.00785.x. PubMed: 10594777.
12. Wilson E, Sudhir K, Ives HE (1995) Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions. J Clin Invest: 96: 2364-2372. doi:10.1172/JCI118293. PubMed: 7593624.
13. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH et al. (2003) Cell migration: integrating signals from front to back. Science: 302: 1704-1709. doi:10.1126/science.1092053. PubMed: 14657486.
14. Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell: 116: 167-179. doi:10.1016/S0092-8674(04)00003-0. PubMed: 14744429.
15. Sawada N, Li Y, Liao JK (2010) Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol: 10: 116-121. doi:10.1016/j.coph.2009.11.004. PubMed: 20060361.
16. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F et al. (2012) Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med: 157: 263-275. doi:10.7326/0003-4819-157-4-201208210-00007. PubMed: 22910937.
17. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K et al. (2005) Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int: 67: 157-166. doi:10.1111/j.1523-1755.2005.00066.x. PubMed: 15610239.
18. Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med: 72: 375-380. doi: 10.1016/0002-9343(82)90490-9. PubMed: 7036732.
19. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE (2000) Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis: 35: 695-707. doi:10.1016/S0272-6386(00)70018-7. PubMed: 10739792.
20. Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care: 26: 2421-2425. doi:10.2337/diacare.26.8.2421. PubMed: 12882873.
21. Anderson RJ, Ray CJ, Popoff MR (2000) Evidence for Rho protein regulation of renal tubular epithelial cell function. Kidney Int: 58: 1996-2006. doi:10.1111/j.1523-1755.2000.00372.x. PubMed: 11044220.
22. Hsu HH, Hoffmann S, Endlich N, Velic A, Schwab A et al. (2008) Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med (Berl): 86: 1379-1394. doi:10.1007/s00109-008-0399-y. PubMed: 18773185.
23. Giehl K, Graness A, Goppelt-Struebe M (2008) The small GTPase Rac-1 is a regulator of mesangial cell morphology and thrombospondin-1 expression. Am J Physiol Renal Physiol: 294: F407-F413. PubMed: 18045834.
24. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H et al. (2008) Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med: 14: 1370-1376. doi:10.1038/nm.1879. PubMed: 19029984.
25. Meyer-Schwesinger C, Dehde S, von RC, Gatzemeier S, Klug P et al. (2009) Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-kappaB p65 signaling. Am J Physiol Renal Physiol: 296: F1088-F1099. doi:10.1152/ajprenal.90746.2008. PubMed: 19225047.
26. Komers R (2011) Rho kinase inhibition in diabetic nephropathy. Curr Opin Nephrol Hypertens: 20: 77-83. doi:10.1097/MNH.0b013e32834131f8. PubMed: 21076299.
27. Peng F, Wu D, Gao B, Ingram AJ, Zhang B et al. (2008) RhoA/Rhokinase contribute to the pathogenesis of diabetic renal disease. Diabetes: 57: 1683-1692. doi:10.2337/db07-1149. PubMed: 18356410.
28. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B et al. (2011) Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int: 79: 432-442. doi:10.1038/ki.2010.428. PubMed: 20962741.
29. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y et al. (2003) Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int: 64: 2009-2019. doi:10.1046/j.1523-1755.2003. 00300.x. PubMed: 14633123.
30. Olson MF (2008) Applications for ROCK kinase inhibition. Curr Opin Cell Biol: 20: 242-248. doi:10.1016/j.ceb.2008.01.002. PubMed: 18282695.
31. Löhn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A et al. (2009) Pharmacological characterization of SAR407899, a novel rhokinase inhibitor. Hypertension: 54: 676-683. doi:10.1161/HYPERTENSIONAHA.109.134353. PubMed: 19597037.
32. Thamilselvan V, Menon M, Thamilselvan S (2012) Selective Rac1 inhibition protects renal tubular epithelial cells from oxalate-induced NADPH oxidase-mediated oxidative cell injury. Urol Res: 40: 415-423. doi:10.1007/s00240-011-0405-7. PubMed: 21814770.
33. Yao HY, Chen L, Xu C, Wang J, Chen J et al. (2011) Inhibition of Rac activity alleviates lipopolysaccharide-induced acute pulmonary injury in mice. Biochim Biophys Acta: 1810: 666-674. doi:10.1016/j.bbagen.2011.03.020. PubMed: 21511011.
34. Binker MG, Binker-Cosen AA, Gaisano HY, Cosen-Binker LI (2008) Inhibition of Rac1 decreases the severity of pancreatitis and pancreatitis-associated lung injury in mice. Exp Physiol: 93: 1091-1103. doi:10.1113/expphysiol.2008.043141. PubMed: 18567599.
35. Zhang QG, Wang R, Han D, Dong Y, Brann DW (2009) Role of Rac1 GTPase in JNK signaling and delayed neuronal cell death following global cerebral ischemia. Brain Res: 1265: 138-147. doi:10.1016/j.brainres.2009.01.033. PubMed: 19368836.
36. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K et al. (2012) Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol: 23: 997-1007. doi:10.1681/ASN.2011070734. PubMed: 22440899.
37. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K et al. (2011) Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest: 121: 3233-3243. doi:10.1172/JCI43124. PubMed: 21765214.
38. Mu Y, Gudey SK, Landström M (2012) Non-Smad signaling pathways. Cell Tissue Res: 347: 11-20. doi:10.1007/s00441-011-1201-y. PubMed: 21701805.
39. Wilkes MC, Repellin CE, Hong M, Bracamonte M, Penheiter SG et al. (2009) Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. Dev Cell: 16: 433-444. doi:10.1016/j.devcel.2009.01.009. PubMed: 19289088.
40. Lee HS (2012) Mechanisms and consequences of TGF-ss overexpression by podocytes in progressive podocyte disease. Cell Tissue Res: 347: 129-140. doi:10.1007/s00441-011-1169-7. PubMed: 21541658.
41. Lv Z, Hu M, Zhen J, Lin J, Wang Q et al. (2012) Rac1/PAK1 signaling promotes epithelial-mesenchymal transition of podocytes in vitro via triggering beta-catenin transcriptional activity under high glucose conditions. Int J Biochem Cell Biol: 45: 255-264. PubMed: 23153508.
42. Liu YZ, Liu M, Zhang YM, Kang L, Chen PZ et al. (2012) Protective Effects of Rosuvastatin in Experimental Renal Failure Rats via Improved Endothelial Function. Biol Res Nurs.
43. Ma LJ, Fogo AB (2003) Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int: 64: 350-355. doi:10.1046/j.1523-1755.2003.00058.x. PubMed: 12787428.
44. Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC et al. (2010) The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol: 299: F528-F535. doi:10.1152/ajpcell. 00504.2009. PubMed: 20554645.
45. Togawa A, Miyoshi J, Ishizaki H, Tanaka M, Takakura A et al. (1999) Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene: 18: 5373-5380. doi:10.1038/sj.onc.1202921. PubMed: 10498891.
46. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W et al. (2001) Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol: 12: 413-422. PubMed: 11181788.
47. Wang YX, Martin-McNulty B, da CV, Vincelette J, Lu X et al. (2005) Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation: 111: 2219-2226. doi: 10.1161/01.CIR.0000163544.17221. BE. PubMed: 15851596.
48. Wu J, Li J, Hu H, Liu P, Fang Y et al. (2012) Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol: 32: 1187-1197. doi:10.1007/s10571-012-9845-z. PubMed: 22552888.
49. Jin S, Ray RM, Johnson LR (2006) Rac1 mediates intestinal epithelial cell apoptosis via JNK. Am J Physiol Gastrointest Liver Physiol: 291: G1137-G1147. doi:10.1152/ajpgi.00031.2006. PubMed: 16798728.
50. Leblond B, Petit S, Picard V, Taverne T, Schweighoffer F (10-9-2004) COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS. PCT/IB2004/000926. Patent.
51. Désiré L, Bourdin J, Loiseau N, Peillon H, Picard V et al. (2005) RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. J Biol Chem: 280: 37516-37525. doi:10.1074/jbc.M507913200. PubMed: 16150730.
52. Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU et al. (2010) Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLOS ONE: 5: e11979. doi: 10.1371/journal.pone. 0011979. PubMed: 20694143.
53. Haas CS, Amann K, Schittny J, Blaser B, Müller U et al. (2003) Glomerular and renal vascular structural changes in alpha8 integri-ndeficient mice. J Am Soc Nephrol: 14: 2288-2296. doi:10.1097/01.ASN.0000082999.46030.FE. PubMed: 12937305.
54. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR et al. (2002) A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol: 161: 799-805. doi:10.1016/S0002-9440(10)64239-3. PubMed: 12213707.